About Savara Pharma
Savara Pharma is a company based in Austin (United States) founded in 2008. Savara Pharma has raised $67.82 million across 14 funding rounds from investors including Texas.gov, Cystic Fibrosis Foundation and Keiretsu Forum. The company has 59 employees as of December 31, 2024. Savara Pharma has completed 1 acquisition, including Serendex Pharmaceuticals. Savara Pharma offers products and services including MOLBREEVI. Savara Pharma operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Austin, United States
- Employees 59 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Savara, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$95.88 M (USD)-75.29as on Dec 31, 2024
-
EBITDA
-$102.92 M (USD)-72.02as on Dec 31, 2024
-
Total Equity Funding
$67.82 M (USD)
in 14 rounds
-
Latest Funding Round
$27 M (USD), Post-IPO
Dec 20, 2019
-
Investors
Texas.gov
& 10 more
-
Employee Count
59
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Savara Pharma
Savara Pharma is a publicly listed company on the NASDAQ with ticker symbol SVRA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Savara Pharma
Savara Pharma offers a comprehensive portfolio of products and services, including MOLBREEVI.
Inhaled recombinant GM-CSF for treating autoimmune pulmonary alveolar proteinosis.
People of Savara Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Savara Pharma
Savara Pharma has successfully raised a total of $67.82M across 14 strategic funding rounds. The most recent funding activity was a Post-IPO round of $27 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Savara Pharma
Savara Pharma has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Texas.gov, Cystic Fibrosis Foundation and Keiretsu Forum.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund focused on the biotechnology sector
|
Locked | Locked | Locked | |
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Locked | Locked | Locked | |
|
Accredited investors are networked for private equity funding opportunities.
|
Locked | Locked | Locked |
Investor details for Savara Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Savara Pharma
Savara Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Serendex Pharmaceuticals.
Investment portfolio details for Savara Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Pharmaceutical drug development company focusing on respiratory conditions
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for Savara Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Savara Pharma
Detailed financials for Savara Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Savara Pharma Comparisons
Peer comparison for Savara Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Savara Pharma
Savara Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Savara Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Savara Pharma
Complete news archive for Savara Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Savara Pharma
Savara Pharma was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Savara Pharma is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Matt Pauls is the current CEO of Savara Pharma.
Savara Pharma is a funded company, having raised a total of $67.82M across 14 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Savara Pharma is 59.
Savara Pharma was founded in 2008 and is headquartered in Austin, United States. Operations are centered in the biotechnology sector, where therapeutics for rare respiratory diseases are developed. The lead product, molgramostim nebulizer solution, is formulated as an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) targeted at autoimmune pulmonary alveolar proteinosis (aPAP). Focus remains on advancing treatments for underserved pulmonary conditions.
Savara Pharma's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Savara Pharma offers MOLBREEVI.
Yes, Savara Pharma is publicly traded on NASDAQ under the ticker symbol SVRA.
Savara Pharma has made 1 acquisition, including Serendex Pharmaceuticals.
Savara Pharma has 11 investors. Key investors include Texas.gov, Cystic Fibrosis Foundation, Keiretsu Forum, EcoR1, and Logos Capital.
The ticker symbol of Savara Pharma is SVRA on NASDAQ.